Trevi Therapeutics, Inc. TRVI Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $19.41M+0.2% | $18.91M-44.5% | $56.87M+254% | $117.06M+803% | $19.37M+40.3% | ||
| $152.37M+81.6% | $169.35M+130% | $138.06M+179% | $86.83M+53.6% | $83.88M+42.2% | ||
| $176.12M+66.7% | $191.66M+75.1% | $198.3M+194% | $207.23M+187% | $105.62M+37.6% | ||
| $265K-4.3% | $178K+13.4% | $213K+22.4% | $239K+20.7% | $277K+35.8% | ||
| $179.61M+67.8% | $193.44M+74.4% | $199.36M+189% | $208.34M+182% | $107M+36.2% | ||
| $2.22M+55.9% | $3.91M+14.6% | $2.71M+67.8% | $2.97M+96.8% | $1.42M-32.7% | ||
| $7.12M+3.6% | $9.75M-7.2% | $9.04M-0.9% | $9.24M+36.9% | $6.87M+30.1% | ||
| $7.48M-0.9% | $10.2M-9.4% | $9.57M-3.7% | $9.85M+28.9% | $7.55M+21.2% | ||
| $128K+28.0% | $128K+36.2% | $128K+70.7% | $122K+67.1% | $100K+44.9% | ||
| -$343M-15.3% | -$329.8M-14.9% | -$321.49M-16.6% | -$309.69M-18.0% | -$297.39M-18.9% | ||
| $172.13M+73.1% | $183.24M+83.9% | $189.79M+222% | $198.49M+200% | $99.46M+37.5% | ||
| $179.61M+67.8% | $193.44M+74.4% | $199.36M+189% | $208.34M+182% | $107M+36.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Trevi Therapeutics, Inc.'s total assets?
- Trevi Therapeutics, Inc. (TRVI) holds $179.6M in total assets, up 67.8% year over year.
- How much debt does Trevi Therapeutics, Inc. have?
- Trevi Therapeutics, Inc. carries $682.0K in total debt against $172.1M of shareholders' equity, a debt-to-equity ratio of 0.00.
- How much cash does Trevi Therapeutics, Inc. have?
- Trevi Therapeutics, Inc. holds $19.4M in cash and equivalents.
- Can Trevi Therapeutics, Inc. cover its short-term obligations?
- Its current ratio is 24.75 — current assets exceed current liabilities.
- Where does Trevi Therapeutics, Inc.'s balance sheet data come from?
- Every line is extracted from Trevi Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.